AbbVie Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: AbbVie Inc. or Travere Therapeutics, Inc.?

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, AbbVie Inc. and Travere Therapeutics, Inc. have demonstrated contrasting approaches to SG&A cost management.

A Decade of Financial Insights

From 2014 to 2023, AbbVie Inc. consistently reported higher SG&A expenses, peaking at approximately $15.3 billion in 2022. In contrast, Travere Therapeutics, Inc. maintained a more modest SG&A expenditure, with a maximum of around $266 million in 2023. Despite the stark difference in absolute numbers, the trend reveals that AbbVie's SG&A costs grew by about 66% over the period, while Travere's expenses increased by approximately 345%.

Strategic Implications

These figures suggest that while AbbVie operates on a larger scale, Travere's rapid growth in SG&A expenses could indicate aggressive expansion strategies or rising operational costs.